Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to ...

In what Science magazine has dubbed “Novo Nordisk’s Canadian Mistake,” Ozempic is soon to come off patent in Canada, opening the door to cheaper generic copycats, after the drug giant reportedly ...

Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...

Hims & Hers (HIMS) stock in focus as the company faces a growing number of lawsuits following Novo Nordisk's (NVO) decision ...

In an echo of the pattern laid last year, following a record-high outlay at the very beginning of the year, TV drug ad ...

NVIDIA Corporation (NASDAQ:NVDA) is one of the 10 Best Semiconductor Stocks to Buy According to Reddit. NVIDIA Corporation ...

Eli Lilly (LLY 0.40%) and Novo Nordisk (NVO 1.97%) are two phenomenal growth stocks that investors probably can't go wrong ...

Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...

Hims & Hers bounced back by 8.64 percent on Monday to close at $52.03 following announcements that it remains open to working ...

Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...

Italian authorities on Monday appointed a special commissioner to help Danish drugmaker Novo Nordisk speedily deliver its ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...